Glycosaminoglycans for treatment of emotional dysfunctions

Details Glycosaminoglycans for treatment of emotional dysfunctions Glycosaminoglycans for treatment of emotional dysfunctions

2004-05-19

2010-10-12

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S023000, C514S056000, C536S123100

Reexamination Certificate

active

07812005

ABSTRACT:
The present invention relates to the use of glycosaminoglycan fractions having an average molecular weight of 2400 (±200) D for the preparation of pharmaceutical compositions suitable for the treatment of emotional dysfunctions, especially depressive disorders, anxiety disorders, anxiety neurosis, agitation, confusion.

REFERENCES:
patent: 4956347 (1990-09-01), Ban et al.
patent: WO 92/21354 (1992-12-01), None
patent: WO 00/69444 (2000-11-01), None
Ricotti, M.P. (1973) “Benzodiazepine, amitriptilina e antiselerotici nel trattamento di pazienti anziani con psicosi depressive: prove con il test di Hamilton,” Riforma Medica 87:1078-1087.
International Search Report from PCT priority application serial No. PCT/EP 2004/050860.
Morgan, C. and Inestrosa, N. C., “Interactions of laminin with the amyloid β peptide. Implications for Alzheimer's disease”Brazilian Journal of Medical and Biological Research(2001) 34:597-601.

Affiliated with

Also associated with

Rating

Glycosaminoglycans for treatment of emotional dysfunctions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glycosaminoglycans for treatment of emotional dysfunctions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycosaminoglycans for treatment of emotional dysfunctions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4212981